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g.2012.0Abstract Type 2 diabetes mellitus (T2DM) is a major public health problem around the world.
The C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR)
gene have been reported to be associated with T2DM and its complications. This study is a case-
control study which was performed to clarify the association between polymorphisms in these
two genes and T2DM among Egyptians. Study population (n= 120) consists of 60 Egyptian dia-
betic patients and 60 healthy controls. The MTHFR C677T and A1298C polymorphisms were gen-
otyped by polymerase chain reaction, followed by enzymatic digestion with HinfI and MboII
enzymes, respectively. C677T and A1298C genetic polymorphisms conveyed an increase in
T2DM risk (OR = 3.5, 95% CI = 1.1–11.6, p= 0.032 and OR= 2.2, 95% CI = 0.7–6.9,
p= 0.004 respectively). Additionally, no signiﬁcant associations between lipid/glucose metabolic
indexes with MTHFR genotypes among diabetic patients were observed. Combined MTHFR gene
polymorphisms revealed higher T2DM risk in homozygous and heterozygous forms compared to
single gene polymorphism with pronounced risk in C677T/CT-A1298C/CC combined form
(OR= 6.56, 95% CI = 0.76–56.2, p 0.041). In conclusion, our data suggest that MTHFR
C677T and A1298C polymorphisms are risk factor for T2DM in Egyptian patients. Also, the
two gene polymorphisms may act synergistically to increase the risk of diabetes. Furthermore, itcology Diagnostic Unit, Ain
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The incidence of Type 2 diabetes mellitus (T2DM) has been
increasing throughout the world [1]. It accounts for over 90–97%
of allDMcases in developed countrieswith higher prevalence rates
in developing countries [2,3]. It is characterized by a decreased pro-
duction of insulin, together with insulin resistance [4,5]. Thismulti-
factorial disease or metabolic syndrome results from a complex
interaction of genetic and environmental factors which inﬂuence
beta-cell mass, insulin secretion, insulin action, fat distribution,
andobesity [6].With the increase inDM, there is alsoa correspond-
ing increase in the related complications suchas cardiovascular dis-
ease, retinopathy, neuropathy, and nephropathy [7].
Elevated homocysteine (Hcy) levels are associated with
endothelial dysfunction [8], insulin resistance [9], prothrombot-
ic state [10], macroangiopathy [11,12] and nephropathy [6,7] in
diabetic patients. Several studies have demonstrated that ele-
vated Hcy levels predict the risk of death or coronary events
in T2DM patients [13–14]. MTHFR gene, located on chromo-
some 1 (1p36.3), encodes for methylenetetrahydrofolate
reductase enzyme and catalyzes the conversion of 5,10-methyl-
enetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate
for homocysteine remethylation to methionine [15].
Twoof themost investigated polymorphisms in theMTHFR
gene are C677T and A1298C. The C677T polymorphism con-
verts an alanine residue to a valine (ALA222VAL), leading to
lower enzymatic activity [16]. Compared with the 677CC wild
genotype, the 677TT homozygous and 677CT heterozygous
genotypes decrease enzyme activity by approximately 70%
and 40%, respectively [17,18]. The prevalence of this polymor-
phism differs among ethnic groups, ranging from 2% to
54.5% [19]. The second polymorphism of the MTHFR gene,
A1298C, causes the substitution of glutamate by an alanine res-
idue (GLU429ALA). 1298AA is the ‘‘normal’’ homozygous,
1298AC the heterozygous, and 1298CC the homozygous for
the ‘‘variant’’. The functional relevance in vivo of the A1298C
allele is less well deﬁned. A1298C affects enzyme function
in vitro to a lesser degree, and individuals carrying the variation
have frequently normal homocysteine and plasma folate con-
centrations [18,20]. The aim of this study was to investigate
the effect of genetic polymorphism at MTHFR C677T as well
as its potential interaction with A1298C on susceptibility to dia-
betes in a cohort of Egyptians.
2. subjects and methods
2.1. Subjects
A total of 60 adult Egyptian T2DM patients (mean age ± SD
46.53 ± 6.53 years) were recruited from the outpatient diabe-
tes clinic of Ain Shams University Hospital in addition to 60
age and sex matched healthy unrelated Egyptian adult subjects
(mean age ± SD 44.76 ± 7.21 years). Informed consent was
obtained from all subjects with approval granted by Ain
Shams Research and Ethics Committee ‘‘Ain-Shams Facultyof Medicine federal number IRB00006444’’, prior to sample
collection. Inclusion criteria: fasting plasma glucose
P126 mg/dl, Hemoglobin A1c P6.5% and/or treatment for
diabetes including diet and/or oral antidiabetic drugs to
achieve glycemic control. Duration of the disease on diabetic
patients was 7.8 ± 2.1 years. Recruitment of patients was re-
stricted by the following criteria: the presence of hyperten-
sion/or taking antihypertensive drugs, diabetic nephropathy
deﬁned by persistent microalbuminuria (Albumin: Creatinine
Ratio in spot urine sample: 2.5–25 mg/mmol in males, 3.5–
35 mg/mmol in females) checked at least on two consecutive
occasions over the previous 6 months. Renal or liver failure,
retinopathy diagnosed by funduscopy examination, cardiovas-
cular disease and intake of hormonal replacement therapy.
Taking hypoglycemic drugs and lipid lowering drugs were
not considered as exclusion criteria.
Detailedmedical history for each groupwas obtained.Weight
and height were measured to calculate the body mass index
(BMI), systolic bloodpressure (SBP) anddiastolic bloodpressure
(DBP) were measured in a sitting position using a mercury col-
umn sphygmomanometer after at least 5 min of rest; two readings
of SBP andDBPwere taken.UsingNICEhypertension guideline
2011, standards for hypertension was SBP P140 mmHg and
DBP P90 mmHg [21]. Clinical and biochemical measurements
of patients with type 2 diabetes were performed after 8 h of fast-
ing. Diagnosis of diabetes was according to the criteria of Amer-
ican diabetes association (Fasting plasma glucose; FPG
P126 mg/dl. Fasting is deﬁned as no caloric intake for at least
8 h) [22]. Control subjects did not have any abnormalities regard-
ing their physical examination, bloodpressure, family history, ur-
ine analysis, and routine laboratory blood tests; none of them
were receiving any medications at the time of participation.
2.2. Methods
Venous blood samples were collected from each subject in
three separate test tubes: one was used for biochemical analy-
sis. The others were collected on EDTA for hemoglobin A1C
and DNA extraction.
2.2.1. Biochemical measurements
Serum urea, creatinine, total Cholesterol, High density lipo-
protein, low density lipoprotein, Triglyceride hemoglobin
A1C and fasting blood sugar were done using C111 analyser
Commercial kits (Roch-Diagnostics, Switzerland).
2.2.2. DNA Extraction
Genomic DNA was extracted from white blood cell pellets by
salting out extraction method [15] using a wizard genomic
DNA extraction kit from Promega. Red blood cell lysis was
done by using red cell lysis buffer (20 mM tris–HCL pH 7.6)
followed by centrifugation. Nuclei lysis was carried out by cell
lysis buffer (10 mM tris–HCl pH 8.0, 1 mM EDTA pH
8.0, 0.1% (w/v) SDS) and proteinase K (20 mg/mL) followed
by centrifugation. Protein was precipitated by protein
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11.5 mL of glacial acetic acid, 28.5 mL of water) followed by
centrifugation. Finally DNA was precipitated by isopropanol
and then ethanol 70% and rehydrated in Tris EDTA buffer
(10 mM tris, 1 mM EDTA pH 8.0) and stored at 20 C.
DNA purity and concentration were determined by the spec-
trophotometer measurement of absorbance at 260 and 280 nm.
2.2.3. Detection of MTHFR C677T and A1298C genetic
polymorphism by restriction fragment length polymerase chain
reaction
0.5–2.0 lg of human genomic DNA was ampliﬁed by polymer-
ase chain reaction on Gene Amp PCR System 9700 thermocy-
cler (Applied Biosystems), Genotyping was based on the
methods described by Frosset et al., [17] and Van der Put
et al., [23] as the target genes were ampliﬁed by PCR followed
by restriction digestion with the endonuclease.
For MTHFR C677T polymorphism Primer sequences were
as follows: The forward primer is 5TGAAGGAGAAGG
TGTCTGCGGGA-30 and reverse primer 50AGGACG
GTGCG GTGAGAGTG-30. PCR was carried out in a 25-lL
reaction volume containing 100 ng of genomic DNA,
0.4 lmol/L of each primer, 0.2 mmol/L of dNTPs, 2 mmol/L
of MgCl2 in 10% PCR buffer and 1 unit of Taq polymerase
(Promega, UK). PCR conditions were optimized for an initial
2 min denaturation at 93 C followed by 35 cycles of denatur-
ation at 93 C for 1 min, annealing at 58 C for 1 min, extension
at 72 C for 1 min with ﬁnal extension at 72 C for 10 min.
12.5 lL of the PCR products were digested with 5 units of
Hinf1 (Promega, UK) overnight at 37 C. RFLP product was
separated on 2% agarose gel and visualized by ethidium bro-
mide staining. Wild type (677CC) produced a single band at
198 bp. Heterozygotes (677CT) produced 198-, 175-, and 23-
bp fragments. Homozygous mutants (677TT) produced 175-
and 23-bp fragments (Fig. 1).
For MTHFR A1298C polymorphism, Primer sequences
were: Forward primer 50-CTT TGG GGA GCT GAA GGA
CTA CTA C-30 and the reverse primer 50-CAC TTTGTGAC-
CATTCCGGTTTG-30. 10 mM TrisÆHCl, 50 mM of KCl,
1 mg/ml of gelatin, 3.0 mM of MgCl2, 200 lM each of dNTP,
and 1.25 units of DNA Taq polymerase (Sigma). PCR condi-
tions were optimized for an initial 2-min denaturation cycle
at 92 C followed by 35 cycles of denaturation at 92 C for
1 min, annealing at 60 C for 1 min, extension at 72 C forFigure 1 Agarose Gel electrophoresis for MTHFR C677T after
digestion with Hinf I. Lane 1: 25 bp DNA marker, lanes 2, 4 and 5
(TT) genotype with two fragments 175 and 23 (faint). Lanes 3, 6
and 12 (CC) genotype with one fragment 198 bp. Lanes 7–11, and
13–15 (CT) genotype with three fragments 198, 175 and 23 bp (not
seen).30 s followed by a 7-min ﬁnal extension at 72 C. 12.5 lL of
PCR product was digested with 2.5 ll of MboII buffer and
2.5 units of MboII restriction enzyme (Promega, UK). RFLP
products was separated on 2% agarose gel and visualized by
ethidium bromide staining. Wild types (1298AA) produced ﬁve
fragments of 56, 31, 30, 28, and 18 bp, heterozygotes (1298AC)
produced six fragments of 84, 56, 31, 30, 28, and 18 bp, and the
homozygous mutants (1298CC) produced four fragments of
84, 31, 30, and 18 bp. The major visible bands were those of
84 and 56 bp (Fig. 2).
2.2.4. Statistical analysis
Data were analyzed using SPSSWin statistical package version
15. Numerical data were expressed as mean, standard devia-
tion and range. Qualitative data were expressed as frequency
and percentage. AGT M235T and ACE I/D genotype frequen-
cies were estimated by gene counting, and the differences be-
tween the studied groups were evaluated by Pearson’s v2 test
and ANOVA test. Allele and genotype frequencies were deter-
mined by allele counting, and the odds ratio (OR) and 95%
conﬁdence interval (CI) were also determined. Concordance
of genotype frequencies with Hardy–Weinberg equilibrium
was tested by v2 test.
3. Results
Clinical and laboratory data of studied groups are summarized
in Table 1. Compared to healthy controls, individuals who
developed diabetes had signiﬁcantly higher mean values of
fasting glucose, HbA1c and triglyceride levels.
Comparing the frequency of different genotypes among pa-
tients and controls (Table 2) revealed that: Evaluation of
MTHFR C677T gene mutations (C/T or T/T compared to
the wild type C/C) revealed that homozygous mutation of
MTHFR C677T gene conferred increased T2DM risk
(OR= 3.5, 95% CI = 1.06–11.57, p= 0.032). Statistically
signiﬁcant difference in C677T/T allele was found between
T2DM and control cases with 2.2 risk for occurrence of
T2DM (OR:2.189, 95% CI:1.17–4.10, p= 0.013). Individuals
homozygous for MTHFR A1298C gene mutation (C/C
homotype) had an increased risk of T2DM (OR= 2.2, 95%
CI = 0.7–6.88, p= 0.168). This risk increase was also
observed with A/C heterotype (OR= 2.5, 95% CI = 1.19–
5.39, p= 0.015). A1298C C allele carry 2.9 fold risk forFigure 2 Agarose gel electrophoresis for A1298C polymorphism
after digestion with MboII. Lane 1:10 bp DNA marker, lanes 2, 8
and 9 (AC) genotype which gave six fragments (84, 56, 31, 30, 28
and 18 bp) lanes 5 and 6 (AA) genotype which gave ﬁve bands (56,
31, 30, 28 and 18 bp) lane 3 (CC) genotype which gave four bands
(84, 31, 30 and 18). The major visible bands were those of 84 bp
and 56 bp.
Table 1 Clinical and laboratory data of study participants––T2DM versus control.
Characteristics T2DM Controls P Value
(n= 60) (n= 104)
Gender
Male (%) 52 (86.67%) 93(89.42%) 0.385
Females (%) 8 (13.33%) 11 (10.58%)
Age (year) 46.53 ± 6.53 44.76 ± 7.21 0.141
Duration of diabetes 7.8 ± 2.1 years –
Systolic blood pressure 136.91 ± 18.02 132.57 ± 13.52 0.191
Diastolic blood pressure 82.55 ± 6.59 82.02 ± 6.75 0.656
BMI (kg/m2) 28.83 ± 3.38 27.27 ± 3.54 0.246
Biochemical proﬁle
Fasting blood sugar (mg/dl) 163.62 ± 61.45 98.53 ± 9.88 <0.001*
HB A1C (%) 6.89 ± 0.89 4.88 ± 0.65 <0.001*
Cholesterol (mg/dl) 197.52 ± 40.50 180.76 ± 47.91 0.317
Triglycerides (mg/dl) 194.26 ± 91.68 119.06 ± 66.61 0.013*
HDL cholesterol (mg/dl) 39.41 ± 8.64 41.87 ± 15.09 0.307
LDL cholesterol (mg/dl) 131.03 ± 41.15 115.77 ± 42.16 0.977
Urea (mg/dl) 21.85 ± 9.08 20.52 ± 9.43 0.972
Creatinine (mg/dl) 0.91 ± 0.15 0.95 ± 0.17 0.229
* Signiﬁcant p-value < 0.05.
Table 2 The frequency of MTHFR C677T and A1298C genotypes in T2DM patients (n= 60) and controls (n= 60).
Item T2DM patients no (%) Controls no (%) OR 95% CI p-Value
Genotypes
MTHFR 677
677 C/C 37 (61.67) 45 (75) 0.536 0.25–1.17 0.116
677 C/T 11(18.33) 11(18.33) 1.00 0.398–2.58 1.02*
677 T/T 12(20) 4 (6.67) 3.5 1.06–11.57 0.032*
T allele 35(29.26) 17(15.8) 2.189 1.17–4.10 0.013*
MTHFR 1298
1298 A/A 20 (33.33) 38 (63.33) 0.29 0.137–0.61 0.001
1298 A/C 30(50) 17(28.33) 2.53 1.19–5.39 0.015*
1298 C/C 10 (16.67) 5 (8.33) 2.2 0.7–6.88 0.168
C allele 50(41.66) 27(22.5) 2.87 1.62–5.07 <0.001*
Combined genotypes
677 CC/1298AA 16(26.67) 28(46.67) 0.42 0.19–0.89 0.023*
677 CC/1298 AC 1(1.67) 7(11.67) 0.19 0.015–1.08 0.028*
677 CC/1298 CC 3(5) 3(5) 1.00 0.19–5.65 0.728
677 CT/1298 AA 18(30) 13(21.67) 2.03 0.88–4.73 0.096
677 CT/1298 AC 6(10) 3 (5) 2.83 0.76–19.26 0.298
677 CT/1298 CC 6(10) 1(1.67) 6.56 0.76–56.22 0.041*
677 TT/ 1298 AA 3(5%) 4(6.67%) 0.73 0.16–3.44 0.697
677 TT/ 1298 AC 4(6.67%) 1(1.67%) 4.21 0.46–38.86 0.171
677 TT/ 1298 CC 3(5%) 0(0%) ND ND ND
* Signiﬁcant p-value < 0.05.
90 N.R. AbdRaboh et al.development of T2DM (OR= 2.87, 95% CI = 1.62–5.07,
p< 0.001).
Dual mutant genotype TT/CC was detected in 5% of cases,
while it was absent in controls. Pronounced risk for T2DM
was evident in C677T/CT-A1298C/CC combined form
(OR= 6.56, 95% CI = 0.76–56.2, p 0.041).
Furthermore, statistical comparison between T2DM pa-
tients with wild type alleles and those with mutant alleles of
MTHFR C677T (CT and TT) or A1298C (AC and CC) genes
revealed no statistically signiﬁcant differences between the twopatient groups, as regards their gender, glucose/lipid indexes,
kidney function or blood pressure (Table 3).
Both groups were tested for the Hardy–Weinberg equilib-
rium (HWE) at the C677T locus. The frequencies of CC, CT
and TT genotypes inT2DM patients were 61.67%, 18.33%
and 20% respectively, and in control subjects were 75%,
18.33% and 6.67% respectively. Marked deviation from
HWE was detected in both T2DM group (p2 = 0.5017,
2pq= 0.4413 and q2 = 0.085) and control group
(p2 = 0.708, 2pq= 0.266 and q2 = 0.025). Regarding
Table 3 Association between MTHFR genetic polymorphisms versus clinical and biochemical parameters in T2DM patients.
C677T genotype A1298C genotype
C/C (n= 37) C/T and T/T (n= 23) p Value A/A (n= 20) A/C and C/C (n= 40) p Value
SBP 139.14 ± 15.86 133.0 ± 21.47 0.289 137.87 ± 18.68 136.11 ± 17.96 0.795
DBP 83.76 ± 5.24 80.42 0.249 83.67 ± 5.22 81.61 ± 7.58 0.287
BMI (kg/m2) 27.11 ± 3.27 27.53 ± 3.88 0.294 26.80 ± 4.33 26.57 ± 2.30 0.176
FBS (mg/dl) 164.25 ± 60.54 158.67 ± 83.09 0.599 180.46 ± 61.06 148.0 ± 59.71 0.558
HB A1C (%) 6.95 ± 0.97 6.77 ± 0.70 0.115 6.97 ± 1.00 6.83 ± 0.79 0.374
Chol (mg/dl) 201.84 ± 38.95 187.87 ± 45.05 0.593 202.21 ± 38.14 192.95 ± 43.83 0.756
TG(mg/dl) 169.62 ± 97.28 163.26 ± 80.61 0.708 183.38 ± 110.47 153.74 ± 70.03 0.057
HDL (mg/dl) 39.43 ± 8.72 39.63 ± 9.13 0.884 41.52 ± 8.66 37.73 ± 8.62 0.432
LDL (mg/dl) 134.80 ± 39.41 116.63 ± 39.72 0.850 126.83 ± 40.73 130.61 ± 40.13 0.648
Urea (mg/dl) 19.81 ± 8.35 25.79 ± 9.43 0.746 20.74 ± 8.91 22.82 ± 9.32 0.669
Creatinine (mg/dl) 0.91 ± 0.13 0.92 ± 0.17 0.414 0.89 ± 0.15 0.93 ± 0.15 0.449
Prevalence of methylenetetrahydrofolate reductase C677T and A1298C 91A1298C locus, when both groups were tested for the HWE the
frequencies of AA, AC and CC genotypes of the A1298C gene
inT2DM patients were 33.33%, 50% and 16.67% respectively,
and in control subjects were 63.33%, 28.33% and 8.33%
respectively. No deviation from HWE was detected in
T2DM group (p2 = 0.340, 2pq= 0.486 and q2 = 0.173) or
in control group (p2 = 0.601, 2pq= 0.348 and q2 = 0.037).
4. Discussion
Type 2 diabetes is a complex disorder accounting for about 90–
95% of all diabetes syndromes. Despite numerous reports sug-
gesting a substantial genetic contribution to the susceptibility
of type 2 diabetes, no major susceptibility genes have been
identiﬁed so far [24]. The role of MTHFR C677T and
A1298C polymorphisms has been widely studied across the
world in different populations, but the results are controver-
sial. A closer association between the MTHFR C677T poly-
morphism and T2DM than for the MTHFR A1298C
polymorphism have been reported and explained by the fact
that C677T polymorphism decreases the enzyme activity more
than does A1298C polymorphism: 70% versus 30% respec-
tively [18]. Indeed, C677T polymorphism is located in the exon
4 coding for the N-terminal catalytic domain of MTHFR en-
zyme, whereas A1298C polymorphism is located in the exon
7 coding for the C-terminal regulatory domain [25].
Our results revealed signiﬁcant difference in the distribution
of MTHFR C677T genotypes (p< 0.001) and mutant T allele
(p= 0.015) between diabetic patients and control subjects.
MTHFR C677T/TT homotype was found to be signiﬁcantly
higher in T2DM patients compared to controls, and conferred
an almost 3.5-fold increased risk for T2DM (OR: 3.5, 95% CI:
1.06–11.57, p-value: 0.032) in accordance with Movva et al.
[26] who found fourfold risk for developing T2DM in Indian
population (OR: 4.0423; 95% CI: 1.8753, 8.7133). Other stud-
ies also have conﬁrmed the association of this polymorphism
with diabetic complications as nephropathy in a Polish popu-
lation [27] and coronary heart disease in a Chinese population
[28] as well as Egyptian population [29]. However, in some pre-
vious case-control studies, MTHFR C677T polymorphism was
not associated with T2DM in different populations: Taiwani
[30], Tunisia [31,32], the Czech Republic [33], Turkey [34], Chi-
na [35], Germany [36], and Brazil [37]. The reason for this dis-
crepancy in the literature may reﬂect a potential gene-
environmental interaction.C677T/TT genotype was more frequent in T2DM patients
than in the healthy controls (20% versus 6.7%). Of interest
to note is that the Brazilian population holds the lowest fre-
quency reported for MTHFR C677T/TT genotype (9%) [37]
and the highest (19.1%) is in Chinese population [28]. Hence,
it can be concluded that ethnicity is one of the most important
factors that play a role in C677T gene polymorphism and sus-
ceptibility to T2DM. The C677T polymorphism of the
MTHFR gene has been reported to cause reduced enzyme
activity and impaired homocysteine/folate metabolism, leading
to moderate hyperhomocysteinemia [38]. However, no litera-
ture data directly associate the MTHFR-linked homocysteine
and folate metabolism with T2DM. This hyperhomocystein-
emia may damage the vascular endothelium, which is respon-
sible for vasopressant effects and may cause a status of
elevated blood pressure [39].
In the current study regarding MTHFR A1298C gene poly-
morphism, a signiﬁcant association with T2DM (p< 0.001)
was evident. The frequency of 1298 CC genotype was higher in
the patients compared to controls (16.67% versus 8.33% respec-
tively) in accordance with previous results in Taiwanese [30] and
Moroccan populations [40]. Calculation of the risk estimate re-
vealed that 1298CC homozygous andAC heterozygous genotype
were associatedwith 2.2 and2.5 times risk forT2DMrespectively.
Few studies have reported the association between
MTHFR A1298C polymorphism and T2DM. In a Polish pop-
ulation, the frequency of the A1298C genotypes did not differ
among patients with different stages of diabetic nephropathy
[27]. However, this polymorphism was reported to be associ-
ated with the risk for development of neural tube defects [23]
and cardiovascular diseases [41].
Our results revealed no signiﬁcant relation between lipid/
glucose metabolic indexes with MTHFR genotypes among
diabetic patients. Thus we can assume that MTHFR polymor-
phisms which may play some roles in the pathogenesis and
complications in Caucasians T2DM patients are unlikely to
be applied in Egyptian patients. Lack of association between
the MTHFR genotypes with diabetic related indexes in our
study could be attributed to ethnic variations in MTHFR
genotypes, as a given population may have elements in its ge-
netic reservoir that are protective against certain disease de-
spite the high prevalence of disease-susceptible alleles [30].
Additionally, linkage disequilibrium of the mutant allele with
a nearby non causative polymorphism may underlie the
ﬁndings. Therefore, the possibility of linkage disequilibrium
92 N.R. AbdRaboh et al.of the variant alleles with a nearby non-causative polymor-
phism in our population cannot be ruled out.
Signiﬁcant difference between diabetic and control groups
for those was found to be heterozygous for 677CT and homo-
zygous for the mutant 1298CC (OR: 6.56, 95% CI: 0.76–56.22,
p-value: 0.041). Double heterozygozity 677 CT/1298 AC
revealed 2.8 risk for T2DM (OR:2.83, 95% CI 0.76–19.26, p-
value:0.298) conﬁrming previous results of Van der Put
et al., [23] who reported that 677CﬁT and 1298AﬁC poly-
morphisms can act synergistically, given that heterozygosity
for both polymorphisms causes lower MTHFR enzymatic
activity than heterozygosity alone for either of them and a
trend to higher or signiﬁcantly higher plasma total homocyste-
ine levels. Also, double heterozygous patients had a higher risk
for diabetic nephropathy than those with the 677CT genotype
[42]. On the contrary, Friedman et al. [43] found that com-
bined heterozygosity of A1298C mutation with other MTHFR
mutations including C677T has been associated with decreased
total plasma homocysteine levels.
MTHFR 677 CC/ 1298 AA combined genotype was signif-
icantly higher in the controls compared to patients with de-
creased risk of T2DM, thus it may have a protective role
against the susceptibility to T2DM. No statistically signiﬁcant
difference could be encountered between the patients and the
controls regarding the frequency of the combined genotypes;
677 CC/ 1298 CC, 677 CT/ 1298 AA, 677 TT/1298 AA and
677 TT/1298 AC. The combined genotypes MTHFR 677
TT/ 1298 CC were not detected in the controls, so the statisti-
cal difference between the two groups and the risk estimates
for these combined genotypes were not determined. This could
be an evidence of increased T2DM risk of this combined geno-
type. In conclusion: our data suggest that the MTHFR C677T
and A1298C polymorphism are risk factor for T2DM in Egyp-
tian patients. Our data also suggest that the two gene polymor-
phisms may act synergistically to increase the risk of diabetes.
Furthermore, it should be noted that the size of the studied
population was relatively small and therefore, large-scale pro-
spective studies are needed to conﬁrm these ﬁndings.
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